Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis

Takehiko Yokobori, Hisae Iinuma, Teppei Shimamura, Seiya Imoto, Keishi Sugimachi, Hideshi Ishii, Masaaki Iwatsuki, Daisuke Ota, Masahisa Ohkuma, Takeshi Iwaya, Naohiro Nishida, Ryunosuke Kogo, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hiroyuki Toh, Tetsuya Sato, Graham F. Barnard, Takeo Fukagawa, Seiichiro YamamotoHayao Nakanishi, Shin Sasaki, Satoru Miyano, Toshiaki Watanabe, Hiroyuki Kuwano, Koshi Mimori, Klaus Pantel, Masaki Mori

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Circulating tumor cells (CTC) in blood have attracted attention both as potential seeds for metastasis and as biomarkers. However, most CTC detection systems might miss epithelial-mesenchymal transition (EMT)-induced metastatic cells because detection is based on epithelial markers. First, to discover novel markers capable of detecting CTCs in which EMT has not been repressed, microarray analysis of 132 colorectal cancers (CRC) from Japanese patients was conducted, and 2,969 genes were detected that were overexpressed relative to normal colon mucosa. From the detected genes, we selected those that were overexpressed CRC with distant metastasis. Then, we analyzed the CRC metastasis-specific genes (n = 22) to determine whether they were expressed in normal circulation. As a result, PLS3 was discovered as a CTC marker that was expressed in metastatic CRC cells but not in normal circulation. Using fluorescent immunocytochemistry, we validated that PLS3 was expressed in EMT-induced CTC in peripheral blood from patients with CRC with distant metastasis. PLS3-expressing cells were detected in the peripheral blood of approximately one-third of an independent set of 711 Japanese patients with CRC. Multivariate analysis showed that PLS3-positive CTC was independently associated with prognosis in the training set (n = 381) and the validation set [n = 330; HR = 2.17; 95% confidence interval (CI) = 1.38-3.40 and HR = 3.92; 95% CI = 2.27-6.85]. The association between PLS3-positive CTC and prognosis was particularly strong in patients with Dukes B (HR = 4.07; 95% CI = 1.50-11.57) and Dukes C (HR = 2.57; 95% CI = 1.42-4.63). PLS3 is a novel marker for metastatic CRC cells, and it possesses significant prognostic value.

Original languageEnglish
Pages (from-to)2059-2069
Number of pages11
JournalCancer Research
Volume73
Issue number7
DOIs
Publication statusPublished - Apr 1 2013

Fingerprint

Circulating Neoplastic Cells
Epithelial-Mesenchymal Transition
Colorectal Neoplasms
Confidence Intervals
Neoplasm Metastasis
Genes
Microarray Analysis
Tumor Biomarkers
Seeds
Colon
Mucous Membrane
Multivariate Analysis
Biomarkers
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. / Yokobori, Takehiko; Iinuma, Hisae; Shimamura, Teppei; Imoto, Seiya; Sugimachi, Keishi; Ishii, Hideshi; Iwatsuki, Masaaki; Ota, Daisuke; Ohkuma, Masahisa; Iwaya, Takeshi; Nishida, Naohiro; Kogo, Ryunosuke; Sudo, Tomoya; Tanaka, Fumiaki; Shibata, Kohei; Toh, Hiroyuki; Sato, Tetsuya; Barnard, Graham F.; Fukagawa, Takeo; Yamamoto, Seiichiro; Nakanishi, Hayao; Sasaki, Shin; Miyano, Satoru; Watanabe, Toshiaki; Kuwano, Hiroyuki; Mimori, Koshi; Pantel, Klaus; Mori, Masaki.

In: Cancer Research, Vol. 73, No. 7, 01.04.2013, p. 2059-2069.

Research output: Contribution to journalArticle

Yokobori, T, Iinuma, H, Shimamura, T, Imoto, S, Sugimachi, K, Ishii, H, Iwatsuki, M, Ota, D, Ohkuma, M, Iwaya, T, Nishida, N, Kogo, R, Sudo, T, Tanaka, F, Shibata, K, Toh, H, Sato, T, Barnard, GF, Fukagawa, T, Yamamoto, S, Nakanishi, H, Sasaki, S, Miyano, S, Watanabe, T, Kuwano, H, Mimori, K, Pantel, K & Mori, M 2013, 'Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis', Cancer Research, vol. 73, no. 7, pp. 2059-2069. https://doi.org/10.1158/0008-5472.CAN-12-0326
Yokobori, Takehiko ; Iinuma, Hisae ; Shimamura, Teppei ; Imoto, Seiya ; Sugimachi, Keishi ; Ishii, Hideshi ; Iwatsuki, Masaaki ; Ota, Daisuke ; Ohkuma, Masahisa ; Iwaya, Takeshi ; Nishida, Naohiro ; Kogo, Ryunosuke ; Sudo, Tomoya ; Tanaka, Fumiaki ; Shibata, Kohei ; Toh, Hiroyuki ; Sato, Tetsuya ; Barnard, Graham F. ; Fukagawa, Takeo ; Yamamoto, Seiichiro ; Nakanishi, Hayao ; Sasaki, Shin ; Miyano, Satoru ; Watanabe, Toshiaki ; Kuwano, Hiroyuki ; Mimori, Koshi ; Pantel, Klaus ; Mori, Masaki. / Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. In: Cancer Research. 2013 ; Vol. 73, No. 7. pp. 2059-2069.
@article{0d4c1b0f4c90440e80de0b7ca0799bfb,
title = "Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis",
abstract = "Circulating tumor cells (CTC) in blood have attracted attention both as potential seeds for metastasis and as biomarkers. However, most CTC detection systems might miss epithelial-mesenchymal transition (EMT)-induced metastatic cells because detection is based on epithelial markers. First, to discover novel markers capable of detecting CTCs in which EMT has not been repressed, microarray analysis of 132 colorectal cancers (CRC) from Japanese patients was conducted, and 2,969 genes were detected that were overexpressed relative to normal colon mucosa. From the detected genes, we selected those that were overexpressed CRC with distant metastasis. Then, we analyzed the CRC metastasis-specific genes (n = 22) to determine whether they were expressed in normal circulation. As a result, PLS3 was discovered as a CTC marker that was expressed in metastatic CRC cells but not in normal circulation. Using fluorescent immunocytochemistry, we validated that PLS3 was expressed in EMT-induced CTC in peripheral blood from patients with CRC with distant metastasis. PLS3-expressing cells were detected in the peripheral blood of approximately one-third of an independent set of 711 Japanese patients with CRC. Multivariate analysis showed that PLS3-positive CTC was independently associated with prognosis in the training set (n = 381) and the validation set [n = 330; HR = 2.17; 95{\%} confidence interval (CI) = 1.38-3.40 and HR = 3.92; 95{\%} CI = 2.27-6.85]. The association between PLS3-positive CTC and prognosis was particularly strong in patients with Dukes B (HR = 4.07; 95{\%} CI = 1.50-11.57) and Dukes C (HR = 2.57; 95{\%} CI = 1.42-4.63). PLS3 is a novel marker for metastatic CRC cells, and it possesses significant prognostic value.",
author = "Takehiko Yokobori and Hisae Iinuma and Teppei Shimamura and Seiya Imoto and Keishi Sugimachi and Hideshi Ishii and Masaaki Iwatsuki and Daisuke Ota and Masahisa Ohkuma and Takeshi Iwaya and Naohiro Nishida and Ryunosuke Kogo and Tomoya Sudo and Fumiaki Tanaka and Kohei Shibata and Hiroyuki Toh and Tetsuya Sato and Barnard, {Graham F.} and Takeo Fukagawa and Seiichiro Yamamoto and Hayao Nakanishi and Shin Sasaki and Satoru Miyano and Toshiaki Watanabe and Hiroyuki Kuwano and Koshi Mimori and Klaus Pantel and Masaki Mori",
year = "2013",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-12-0326",
language = "English",
volume = "73",
pages = "2059--2069",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis

AU - Yokobori, Takehiko

AU - Iinuma, Hisae

AU - Shimamura, Teppei

AU - Imoto, Seiya

AU - Sugimachi, Keishi

AU - Ishii, Hideshi

AU - Iwatsuki, Masaaki

AU - Ota, Daisuke

AU - Ohkuma, Masahisa

AU - Iwaya, Takeshi

AU - Nishida, Naohiro

AU - Kogo, Ryunosuke

AU - Sudo, Tomoya

AU - Tanaka, Fumiaki

AU - Shibata, Kohei

AU - Toh, Hiroyuki

AU - Sato, Tetsuya

AU - Barnard, Graham F.

AU - Fukagawa, Takeo

AU - Yamamoto, Seiichiro

AU - Nakanishi, Hayao

AU - Sasaki, Shin

AU - Miyano, Satoru

AU - Watanabe, Toshiaki

AU - Kuwano, Hiroyuki

AU - Mimori, Koshi

AU - Pantel, Klaus

AU - Mori, Masaki

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Circulating tumor cells (CTC) in blood have attracted attention both as potential seeds for metastasis and as biomarkers. However, most CTC detection systems might miss epithelial-mesenchymal transition (EMT)-induced metastatic cells because detection is based on epithelial markers. First, to discover novel markers capable of detecting CTCs in which EMT has not been repressed, microarray analysis of 132 colorectal cancers (CRC) from Japanese patients was conducted, and 2,969 genes were detected that were overexpressed relative to normal colon mucosa. From the detected genes, we selected those that were overexpressed CRC with distant metastasis. Then, we analyzed the CRC metastasis-specific genes (n = 22) to determine whether they were expressed in normal circulation. As a result, PLS3 was discovered as a CTC marker that was expressed in metastatic CRC cells but not in normal circulation. Using fluorescent immunocytochemistry, we validated that PLS3 was expressed in EMT-induced CTC in peripheral blood from patients with CRC with distant metastasis. PLS3-expressing cells were detected in the peripheral blood of approximately one-third of an independent set of 711 Japanese patients with CRC. Multivariate analysis showed that PLS3-positive CTC was independently associated with prognosis in the training set (n = 381) and the validation set [n = 330; HR = 2.17; 95% confidence interval (CI) = 1.38-3.40 and HR = 3.92; 95% CI = 2.27-6.85]. The association between PLS3-positive CTC and prognosis was particularly strong in patients with Dukes B (HR = 4.07; 95% CI = 1.50-11.57) and Dukes C (HR = 2.57; 95% CI = 1.42-4.63). PLS3 is a novel marker for metastatic CRC cells, and it possesses significant prognostic value.

AB - Circulating tumor cells (CTC) in blood have attracted attention both as potential seeds for metastasis and as biomarkers. However, most CTC detection systems might miss epithelial-mesenchymal transition (EMT)-induced metastatic cells because detection is based on epithelial markers. First, to discover novel markers capable of detecting CTCs in which EMT has not been repressed, microarray analysis of 132 colorectal cancers (CRC) from Japanese patients was conducted, and 2,969 genes were detected that were overexpressed relative to normal colon mucosa. From the detected genes, we selected those that were overexpressed CRC with distant metastasis. Then, we analyzed the CRC metastasis-specific genes (n = 22) to determine whether they were expressed in normal circulation. As a result, PLS3 was discovered as a CTC marker that was expressed in metastatic CRC cells but not in normal circulation. Using fluorescent immunocytochemistry, we validated that PLS3 was expressed in EMT-induced CTC in peripheral blood from patients with CRC with distant metastasis. PLS3-expressing cells were detected in the peripheral blood of approximately one-third of an independent set of 711 Japanese patients with CRC. Multivariate analysis showed that PLS3-positive CTC was independently associated with prognosis in the training set (n = 381) and the validation set [n = 330; HR = 2.17; 95% confidence interval (CI) = 1.38-3.40 and HR = 3.92; 95% CI = 2.27-6.85]. The association between PLS3-positive CTC and prognosis was particularly strong in patients with Dukes B (HR = 4.07; 95% CI = 1.50-11.57) and Dukes C (HR = 2.57; 95% CI = 1.42-4.63). PLS3 is a novel marker for metastatic CRC cells, and it possesses significant prognostic value.

UR - http://www.scopus.com/inward/record.url?scp=84875999237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875999237&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-0326

DO - 10.1158/0008-5472.CAN-12-0326

M3 - Article

C2 - 23378342

AN - SCOPUS:84875999237

VL - 73

SP - 2059

EP - 2069

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 7

ER -